Overview

Study of Silodosin to Facilitate Passage of Urinary Stones

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Watson Pharmaceuticals
Treatments:
Silodosin